Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57

1.

Interferon lambda 4 impacts the genetic diversity of hepatitis C virus.

Ansari MA, Aranday-Cortes E, Ip CL, da Silva Filipe A, Lau SH, Bamford C, Bonsall D, Trebes A, Piazza P, Sreenu V, Cowton VM; STOP-HCV Consortium, Ball J, Barnes E, Burgess G, Cooke G, Dillon J, Foster G, Gore C, Guha N, Halford R, Holmes C, Hudson E, Hutchinson S, Irving W, Khakoo S, Klenerman P, Martin N, Mbisa T, McKeating J, McLauchlan J, Miners A, Murray A, Shaw P, Simmonds P, Smith S, Spencer C, Thomson E, Troke P, Vickerman P, Zitzmann N, Hudson E, Bowden R, Patel AH, Foster GR, Irving WL, Agarwal K, Thomson EC, Simmonds P, Klenerman P, Holmes C, Barnes E, Spencer CC, McLauchlan J, Pedergnana V.

Elife. 2019 Sep 3;8. pii: e42463. doi: 10.7554/eLife.42463.

2.

Neutrophils differentially attenuate immune response to Aspergillus infection through complement receptor 3 and induction of myeloperoxidase.

Goh JG, Ravikumar S, Win MS, Cao Q, Tan AL, Lim JHJ, Leong W, Herbrecht R, Troke PF, Kullberg BJ, Netea MG, Chng WJ, Dan YY, Chai LYA.

Cell Microbiol. 2018 Mar;20(3). doi: 10.1111/cmi.12798. Epub 2017 Dec 20.

PMID:
29088499
3.

Voriconazole or amphotericin B as primary therapy yields distinct early serum galactomannan trends related to outcomes in invasive aspergillosis.

Chai LY, Kullberg BJ, Earnest A, Johnson EM, Teerenstra S, Vonk AG, Schlamm HT, Herbrecht R, Netea MG, Troke PF.

PLoS One. 2014 Feb 28;9(2):e90176. doi: 10.1371/journal.pone.0090176. eCollection 2014.

4.

Tissue penetration of antifungal agents.

Felton T, Troke PF, Hope WW.

Clin Microbiol Rev. 2014 Jan;27(1):68-88. doi: 10.1128/CMR.00046-13. Review.

5.

Improvement in the outcome of invasive fusariosis in the last decade.

Nucci M, Marr KA, Vehreschild MJ, de Souza CA, Velasco E, Cappellano P, Carlesse F, Queiroz-Telles F, Sheppard DC, Kindo A, Cesaro S, Hamerschlak N, Solza C, Heinz WJ, Schaller M, Atalla A, Arikan-Akdagli S, Bertz H, Galvão Castro C Jr, Herbrecht R, Hoenigl M, Härter G, Hermansen NE, Josting A, Pagano L, Salles MJ, Mossad SB, Ogunc D, Pasqualotto AC, Araujo V, Troke PF, Lortholary O, Cornely OA, Anaissie E.

Clin Microbiol Infect. 2014 Jun;20(6):580-5. doi: 10.1111/1469-0691.12409. Epub 2013 Nov 18.

6.

An elevated pro-inflammatory cytokine response is linked to development of amphotericin B-induced nephrotoxicity.

Chai LY, Netea MG, Tai BC, Khin LW, Vonk AG, Teo BW, Schlamm HT, Herbrecht R, Donnelly JP, Troke PF, Kullberg BJ.

J Antimicrob Chemother. 2013 Jul;68(7):1655-9. doi: 10.1093/jac/dkt055. Epub 2013 Apr 3.

PMID:
23557927
7.

The efficacy of voriconazole in 24 ocular Fusarium infections.

Troke P, Obenga G, Gaujoux T, Goldschmidt P, Bienvenu AL, Cornet M, Grenouillet F, Pons D, Ranque S, Sitbon K, Chaumeil C, Borderie V, Lortholary O.

Infection. 2013 Feb;41(1):15-20. doi: 10.1007/s15010-012-0273-2. Epub 2012 Jun 21.

PMID:
22718362
8.

Early serum galactomannan trend as a predictor of outcome of invasive aspergillosis.

Chai LY, Kullberg BJ, Johnson EM, Teerenstra S, Khin LW, Vonk AG, Maertens J, Lortholary O, Donnelly PJ, Schlamm HT, Troke PF, Netea MG, Herbrecht R.

J Clin Microbiol. 2012 Jul;50(7):2330-6. doi: 10.1128/JCM.06513-11. Epub 2012 May 2.

9.

In vitro characterization of the activity of PF-05095808, a novel biological agent for hepatitis C virus therapy.

Lavender H, Brady K, Burden F, Delpuech-Adams O, Denise H, Palmer A, Perkins H, Savic B, Scott S, Smith-Burchnell C, Troke P, Wright JF, Suhy D, Corbau R.

Antimicrob Agents Chemother. 2012 Mar;56(3):1364-75. doi: 10.1128/AAC.05357-11. Epub 2011 Dec 27.

10.

Characterization of resistance to the nonnucleoside NS5B inhibitor filibuvir in hepatitis C virus-infected patients.

Troke PJ, Lewis M, Simpson P, Gore K, Hammond J, Craig C, Westby M.

Antimicrob Agents Chemother. 2012 Mar;56(3):1331-41. doi: 10.1128/AAC.05611-11. Epub 2011 Dec 27.

11.

Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients.

Troke PF, Hockey HP, Hope WW.

Antimicrob Agents Chemother. 2011 Oct;55(10):4782-8. doi: 10.1128/AAC.01083-10. Epub 2011 Jul 18. Erratum in: Antimicrob Agents Chemother. 2011 Nov;55(11):5415.

12.

The efficacy of voriconazole in the treatment of 192 fungal central nervous system infections: a retrospective analysis.

Schwartz S, Reisman A, Troke PF.

Infection. 2011 Jun;39(3):201-10. doi: 10.1007/s15010-011-0108-6. Epub 2011 Apr 22.

PMID:
21512792
13.

Antiviral activity of the hepatitis C virus polymerase inhibitor filibuvir in genotype 1-infected patients.

Wagner F, Thompson R, Kantaridis C, Simpson P, Troke PJ, Jagannatha S, Neelakantan S, Purohit VS, Hammond JL.

Hepatology. 2011 Jul;54(1):50-9. doi: 10.1002/hep.24342.

PMID:
21488067
14.

DNA-binding and regulatory properties of the transcription factor and putative tumor suppressor p150(Sal2).

Gu H, Li D, Sung CK, Yim H, Troke P, Benjamin T.

Biochim Biophys Acta. 2011 Apr-Jun;1809(4-6):276-83. doi: 10.1016/j.bbagrm.2011.02.002. Epub 2011 Mar 31.

15.

Early proinflammatory cytokines and C‐reactive protein trends as predictors of outcome in invasive Aspergillosis.

Chai L, Netea MG, Teerenstra S, Earnest A, Vonk AG, Schlamm HT, Herbrecht R, Troke PF, Kullberg BJ.

J Infect Dis. 2010 Nov 1;202(9):1454-62. doi: 10.1086/656527.

PMID:
20879853
16.

International retrospective analysis of 73 cases of invasive fusariosis treated with voriconazole.

Lortholary O, Obenga G, Biswas P, Caillot D, Chachaty E, Bienvenu AL, Cornet M, Greene J, Herbrecht R, Lacroix C, Grenouillet F, Raad I, Sitbon K, Troke P; French Mycoses Study Group.

Antimicrob Agents Chemother. 2010 Oct;54(10):4446-50. doi: 10.1128/AAC.00286-10. Epub 2010 Jul 12.

17.

Pharmacokinetics and safety of 14 days intravenous voriconazole in allogeneic haematopoietic stem cell transplant recipients.

Brüggemann RJ, Blijlevens NM, Burger DM, Franke B, Troke PF, Donnelly JP.

J Antimicrob Chemother. 2010 Jan;65(1):107-13. doi: 10.1093/jac/dkp416.

PMID:
19933691
18.

Association of mannose-binding lectin deficiency with acute invasive aspergillosis in immunocompromised patients.

Lambourne J, Agranoff D, Herbrecht R, Troke PF, Buchbinder A, Willis F, Letscher-Bru V, Agrawal S, Doffman S, Johnson E, White PL, Barnes RA, Griffin G, Lindsay JA, Harrison TS.

Clin Infect Dis. 2009 Nov 15;49(10):1486-91. doi: 10.1086/644619.

PMID:
19827955
19.

Class III phosphatidylinositol 4-kinase alpha and beta are novel host factor regulators of hepatitis C virus replication.

Borawski J, Troke P, Puyang X, Gibaja V, Zhao S, Mickanin C, Leighton-Davies J, Wilson CJ, Myer V, Cornellataracido I, Baryza J, Tallarico J, Joberty G, Bantscheff M, Schirle M, Bouwmeester T, Mathy JE, Lin K, Compton T, Labow M, Wiedmann B, Gaither LA.

J Virol. 2009 Oct;83(19):10058-74. doi: 10.1128/JVI.02418-08. Epub 2009 Jul 15.

20.

Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies.

Johnson E, Espinel-Ingroff A, Szekely A, Hockey H, Troke P.

Int J Antimicrob Agents. 2008 Dec;32(6):511-4. doi: 10.1016/j.ijantimicag.2008.05.023. Epub 2008 Sep 13.

PMID:
18790613
21.

Activities of voriconazole, itraconazole and amphotericin B in vitro against 590 moulds from 323 patients in the voriconazole Phase III clinical studies.

Espinel-Ingroff A, Johnson E, Hockey H, Troke P.

J Antimicrob Chemother. 2008 Mar;61(3):616-20. doi: 10.1093/jac/dkm518. Epub 2008 Jan 25.

PMID:
18222957
22.

Treatment of scedosporiosis with voriconazole: clinical experience with 107 patients.

Troke P, Aguirrebengoa K, Arteaga C, Ellis D, Heath CH, Lutsar I, Rovira M, Nguyen Q, Slavin M, Chen SC; Global Scedosporium Study Group.

Antimicrob Agents Chemother. 2008 May;52(5):1743-50. doi: 10.1128/AAC.01388-07. Epub 2008 Jan 22.

23.

Poor efficacy of amphotericin B-based therapy in CNS aspergillosis.

Schwartz S, Ruhnke M, Ribaud P, Reed E, Troke P, Thiel E.

Mycoses. 2007 May;50(3):196-200.

PMID:
17472616
24.

Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign.

Greene RE, Schlamm HT, Oestmann JW, Stark P, Durand C, Lortholary O, Wingard JR, Herbrecht R, Ribaud P, Patterson TF, Troke PF, Denning DW, Bennett JE, de Pauw BE, Rubin RH.

Clin Infect Dis. 2007 Feb 1;44(3):373-9. Epub 2006 Dec 29.

PMID:
17205443
25.

MOZ fusion proteins in acute myeloid leukaemia.

Troke PJ, Kindle KB, Collins HM, Heery DM.

Biochem Soc Symp. 2006;(73):23-39. Review.

PMID:
16626284
26.

MOZ-TIF2 alters cofactor recruitment and histone modification at the RARbeta2 promoter: differential effects of MOZ fusion proteins on CBP- and MOZ-dependent activators.

Collins HM, Kindle KB, Matsuda S, Ryan C, Troke PJ, Kalkhoven E, Heery DM.

J Biol Chem. 2006 Jun 23;281(25):17124-33. Epub 2006 Apr 13.

27.

Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints.

Pfaller MA, Diekema DJ, Rex JH, Espinel-Ingroff A, Johnson EM, Andes D, Chaturvedi V, Ghannoum MA, Odds FC, Rinaldi MG, Sheehan DJ, Troke P, Walsh TJ, Warnock DW.

J Clin Microbiol. 2006 Mar;44(3):819-26.

28.
29.

Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome.

Patterson TF, Boucher HW, Herbrecht R, Denning DW, Lortholary O, Ribaud P, Rubin RH, Wingard JR, DePauw B, Schlamm HT, Troke P, Bennett JE; European Organization for Research and Treatment of Cancer (EORTC) Invasive Fungal Infections Group (IFIG); Pfizer Global Aspergillus Study Group.

Clin Infect Dis. 2005 Nov 15;41(10):1448-52. Epub 2005 Oct 13.

PMID:
16231256
30.

Improved outcome in central nervous system aspergillosis, using voriconazole treatment.

Schwartz S, Ruhnke M, Ribaud P, Corey L, Driscoll T, Cornely OA, Schuler U, Lutsar I, Troke P, Thiel E.

Blood. 2005 Oct 15;106(8):2641-5. Epub 2005 Jul 5.

31.

Economic evaluation of voriconazole compared with conventional amphotericin B for the primary treatment of aspergillosis in immunocompromised patients.

Wenzel R, Del Favero A, Kibbler C, Rogers T, Rotstein C, Mauskopf J, Morris S, Schlamm H, Troke P, Marciniak A.

J Antimicrob Chemother. 2005 Mar;55(3):352-61. Epub 2005 Feb 22.

PMID:
15728146
32.

MOZ-TIF2 inhibits transcription by nuclear receptors and p53 by impairment of CBP function.

Kindle KB, Troke PJ, Collins HM, Matsuda S, Bossi D, Bellodi C, Kalkhoven E, Salomoni P, Pelicci PG, Minucci S, Heery DM.

Mol Cell Biol. 2005 Feb;25(3):988-1002.

33.

A Conserved alpha-helical motif mediates the binding of diverse nuclear proteins to the SRC1 interaction domain of CBP.

Matsuda S, Harries JC, Viskaduraki M, Troke PJ, Kindle KB, Ryan C, Heery DM.

J Biol Chem. 2004 Apr 2;279(14):14055-64. Epub 2004 Jan 13.

34.

Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients.

Lutsar I, Roffey S, Troke P.

Clin Infect Dis. 2003 Sep 1;37(5):728-32. Epub 2003 Aug 7.

PMID:
12942409
35.

Safety of voriconazole and dose individualization.

Lutsar I, Hodges MR, Tomaszewski K, Troke PF, Wood ND.

Clin Infect Dis. 2003 Apr 15;36(8):1087-8. No abstract available.

PMID:
12684928
36.

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.

Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, Kern WV, Marr KA, Ribaud P, Lortholary O, Sylvester R, Rubin RH, Wingard JR, Stark P, Durand C, Caillot D, Thiel E, Chandrasekar PH, Hodges MR, Schlamm HT, Troke PF, de Pauw B; Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group.

N Engl J Med. 2002 Aug 8;347(6):408-15.

37.

A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients.

Ally R, Schürmann D, Kreisel W, Carosi G, Aguirrebengoa K, Dupont B, Hodges M, Troke P, Romero AJ; Esophageal Candidiasis Study Group.

Clin Infect Dis. 2001 Nov 1;33(9):1447-54. Epub 2001 Sep 26.

PMID:
11577374
38.

Treatment of fluconazole-resistant candidiasis with voriconazole in patients with AIDS.

Hegener P, Troke PF, Fätkenheuer G, Diehl V, Ruhnke M.

AIDS. 1998 Nov 12;12(16):2227-8. No abstract available.

PMID:
9833866
40.

Fluconazole: its properties and efficacy in vaginal candidiasis.

Troke PF.

Curr Probl Dermatol. 1996;24:203-8. Review. No abstract available.

PMID:
8743271
41.

Combination therapy of murine invasive candidiasis with fluconazole and amphotericin B.

Sugar AM, Hitchcock CA, Troke PF, Picard M.

Antimicrob Agents Chemother. 1995 Mar;39(3):598-601.

42.

Fluconazole-insensitive OPC in AIDS patients.

Troke PF, Hitchcock CA.

J Infect. 1994 Mar;28(2):223-7. No abstract available.

PMID:
8080544
43.

Fluconazole resistance in Candida glabrata.

Hitchcock CA, Pye GW, Troke PF, Johnson EM, Warnock DW.

Antimicrob Agents Chemother. 1993 Sep;37(9):1962-5.

44.

Standardized susceptibility testing of fluconazole: an international collaborative study.

Pfaller MA, Dupont B, Kobayashi GS, Müller J, Rinaldi MG, Espinel-Ingroff A, Shadomy S, Troke PF, Walsh TJ, Warnock DW.

Antimicrob Agents Chemother. 1992 Sep;36(9):1805-9.

45.

HIV-1 proteinase is required for synthesis of pro-viral DNA.

Baboonian C, Dalgleish A, Bountiff L, Gross J, Oroszlan S, Rickett G, Smith-Burchnell C, Troke P, Merson J.

Biochem Biophys Res Commun. 1991 Aug 30;179(1):17-24. Erratum in: Biochem Biophys Res Commun 1992 Sep 16;187(2):1200.

PMID:
1652947
46.

Fluconazole and other azoles: translation of in vitro activity to in vivo and clinical efficacy.

Troke PF, Andrews RJ, Pye GW, Richardson K.

Rev Infect Dis. 1990 Mar-Apr;12 Suppl 3:S276-80. Review.

PMID:
2184505
47.

Discovery of fluconazole, a novel antifungal agent.

Richardson K, Cooper K, Marriott MS, Tarbit MH, Troke PF, Whittle PJ.

Rev Infect Dis. 1990 Mar-Apr;12 Suppl 3:S267-71. Review.

PMID:
2184503
48.
49.

Interaction of microsomal cytochrome P-450 isolated from Aspergillus fumigatus with fluconazole and itraconazole.

Ballard SA, Kelly SL, Ellis SW, Troke PF.

J Med Vet Mycol. 1990;28(4):327-34.

PMID:
2176687
50.

In vitro potency and in vivo activity of azoles.

Troke PF, Marriott MS, Richardson K, Tarbit MH.

Ann N Y Acad Sci. 1988;544:284-93. No abstract available.

PMID:
3063173

Supplemental Content

Support Center